Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by biorunon Aug 08, 2022 10:49am
226 Views
Post# 34878643

The CEO Interview

The CEO Interviewhere is the piece I keep coming back to, extracted from the PRC interview post deal. Stripping back any doubt, there is something real here in my opinion...18 cents sounds a little shy of forward earnings:


Let’s talk numbers. Can you elaborate on the actual figures?
HV: Do you see this smile on my face? I can assure everyone that AbbVie is rewarding Sirona Biochem appropriately for our breakthrough technology. Although I am contractually bound to not comment on how much we are receiving, suffice it to say that it will be substantial given that we are getting royalty payments on the global sales of AbbVie’s products based on our patents.
AbbVie has an agreement that allows them to commercialize and market TFC-1067 worldwide into their established global network.
<< Previous
Bullboard Posts
Next >>